International Session（Panel Discussion）1(JSH・JSGE・JSGCS)
Fri. November 6th   9:40 - 12:00   Room 8: Portopia Hotel Main Building Kairaku 1+2
IS-PD1-9_H
 Risk prediction of hepatitis B virus related hepatocellular carcinoma during nucleos(t)ide analogues treatment by aldose reductase measurement
Kazunori Kawaguchi1, Masao Honda1, Shuichi Kaneko1
1Department of Gastroenterology, Kanazawa University School of Medical Sciences
Background: Many cases exhibit hepatocellular carcinoma (HCC) incidence despite under nucleos(t)ide analogue (NA) treatment. Our finding from microarray analysis introduced Aldo-keto reductase family 1 member B10 (AKR1B10) upregulation was noted in advanced liver disease and HCC. Therefore, we analyzed HBV related HCC progression under NA treatment in this biomarker and whether any related pathogenesis observed.
Methods: We analyzed the serum of 97 patients treated with NAs, and patients of HCC incidence were observed in 18 cases receiving NAs. We analyzed serum AKR1B10 values and any localization in HBV infected cells in vitro.
Results: Serum AKR1B10 level was significantly increased in HCC patients compared with non-HCC patients during NA treatment (p<0.001). Histological assessment of the liver revealed that elevated AKR1B10 level was significantly associated with advanced liver fibrosis (p<0.05). Multivariate analysis revealed that elevated AKR1B10 level was a significant factor in HCC incidence (p<0.05) as well as serum WFA+-M2BP (M2BPGi). We confirmed by in-vitro experiment using HBV infected cells and administered AKR1B10 inhibiting compounds and found that AKR1B10 inhibiting effects were similar after administrating Tenofovir (TDF/TAF) and Entecavir (ETV), that localized in cytoplasm, especially around the endoplasmic reticulum.
Conclusion: AKR1B10 is a useful biomarker for risk predicting and monitoring the incidence of HBV-related HCC under NA treatment and this has any role of association with NA effect.
Index Term 1: HBV
Index Term 2: nucleos(t)ide analogues
Page Top